Pyrimidine derivatives as kinase inhibitors and their therapeutical applications

A compound of the formula

• or a pharmaceutically acceptable salt thereof, wherein:
• W is selected from the group consisting of:
• Cl, Br, I, CN, and CONH2;
• Ar represents heteroaryl or aryl, each of which is substituted with from 0 to 4 substituents independently chosen from the group consisting of:
• (1) halogen, hydroxy, amino, amide, cyano, —COOH, —SO2NH2, oxo, nitro or alkoxycarbonyl;
• (2) NR1;
• and
• (3) groups of the formula
• wherein:
• R1 represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, alkylthio, aryl, or arylalkyl;
• R4 represents hydrogen, C1-C4 alkyl, or oxo;
• X—R3 is CH;
• or X—R3 is O;
• or X is N, and R3 represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 aryl or heteroaryl, (C3-C7 cycloalkyl)C1-C4 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio, C2-C6 alkanoyl, C1-C6 alkoxycarbonyl, C2-C6 alkanoyloxy, mono- and di-(C3-C8 cycloalkyl)aminoC0-C4alkyl, (4- to 7-membered heterocycle)C0-C4alkyl, C1-C6 alkylsulfonyl, mono- and di-(C1-C6 alkyl) sulfonamido, and mono- and di-(C1-C6 alkyl)aminocarbonyl, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, —COOH or oxo;
• R5 and R6 are independently selected from the group consisting of:
• hydrogen, F, Cl, and Br;
• and
• R7, R8 and R9 are independently selected from the group consisting of:
• hydrogen and CH3.